Last reviewed · How we verify

TRUVADA + Raltegravir — Competitive Intelligence Brief

TRUVADA + Raltegravir (TRUVADA + Raltegravir) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy (NRTI + INSTI). Area: Infectious Disease / Virology.

marketed Antiretroviral combination therapy (NRTI + INSTI) HIV reverse transcriptase and HIV integrase Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

TRUVADA + Raltegravir (TRUVADA + Raltegravir) — Fenway Community Health. This combination blocks HIV replication by inhibiting reverse transcriptase (TRUVADA) and integrase (raltegravir), preventing the virus from copying itself and integrating into host DNA.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
TRUVADA + Raltegravir TARGET TRUVADA + Raltegravir Fenway Community Health marketed Antiretroviral combination therapy (NRTI + INSTI) HIV reverse transcriptase and HIV integrase
Tenofovir, Emtricitabine, Raltegravir Tenofovir, Emtricitabine, Raltegravir Hospital Clinic of Barcelona marketed Antiretroviral combination therapy (NRTI/NtRTI + INSTI) HIV reverse transcriptase and HIV integrase
Switch to Triumeq Switch to Triumeq McGill University Health Centre/Research Institute of the McGill University Health Centre marketed Antiretroviral combination therapy (NRTI + INSTI) HIV reverse transcriptase, HIV integrase
ABC/DTG/3TC FDC ABC/DTG/3TC FDC ViiV Healthcare phase 3 Antiretroviral combination therapy (NRTI + INSTI) HIV reverse transcriptase, HIV integrase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy (NRTI + INSTI) class)

  1. Fenway Community Health · 1 drug in this class
  2. McGill University Health Centre/Research Institute of the McGill University Health Centre · 1 drug in this class
  3. ViiV Healthcare · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TRUVADA + Raltegravir — Competitive Intelligence Brief. https://druglandscape.com/ci/truvada-raltegravir. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: